| Name | Title | Contact Details |
|---|
Calvert Memorial Hospital is a private, not-for-profit, community-owned hospital. Founded in 1919, CMH has been taking care of Southern Maryland families for more than 90 years. Our hospital is accredited by The Joint Commission, licensed by the Maryland Department of Health and Mental Hygiene and certified for Medicare and Medicaid. You can feel confident that you will receive only the highest quality care at CMH. There are 267 active and consulting physicians representing over 40 different specialties. Over 1,000 dedicated employees help CMH provide the very best for our patients. An additional 176 volunteers help add those "special touches" you will notice during your stay here. CMH is governed by a community board of directors who volunteer their service to the hospital. They represent our community and take an active role in the operation of our facility. You can find out more about our board members at www.calverthospital.org. In addition to our main hospital campus, satellite medical office buildings in Dunkirk, Solomons, Twin Beaches and Prince Frederick ensure that quality care is no more than 15 minutes from anywhere in Calvert County. We are dedicated to the seamless delivery of high quality medical services for each of our patients. This means supplying everything you may need, from acute, critical care to rehabilitation and home health services, all in the same continuum. It also means providing community health education, wellness programs and reaching out to our neighbors through community partnerships.
Grant Regional Health Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Grant Regional Health Center is based in Lancaster, WI. You can find more information on Grant Regional Health Center at www.grantregional.com
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our strength lies in our exclusive focus and singular influence on the worldwide effort to end T1D.
Eksigent Technologies is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.